by Certifié Conforme | 13 May Tue | English
Proceeds will support two Phase 3 pivotal programs with nizubaglustat, lead asset in Niemann-Pick disease Type C disease and GM1/GM2 gangliosidoses, three forms of rare lysosomal storage disorders, as well as expanding Azafaros pipeline to other indications The...
by Certifié Conforme | 12 May Mon | English
Paris, May 12 2024 – Jeito Capital (“Jeito”), a global leading independent Private Equity fund dedicated to biopharma, is pleased to announce the promotion of Mehdi Ainouche to Partner and Julien Elric to Senior Principal. These promotions represent the next...
by Manon FRACHON | 24 Mar Mon | English
Proceeds from the financing will advance Augustine’s lead candidate, AGT-100216, through a Phase 2 proof-of-concept clinical trial in Charcot-Marie-Tooth and support significant pipeline expansion into cardio-metabolic and neurodegenerative diseases. This investment...
by Manon FRACHON | 3 Mar Mon | English
Callio Therapeutics is a biotechnology company developing multi-payload ADCs with technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience. Investment will contribute to achieve clinical proof-of-concept for Callio’s HER-2-targeted...
by Manon FRACHON | 7 Jan Tue | English
Proceeds of financing will support two double-blinded Phase 2 trials for its lead candidate XC001, a pioneering transformative gene therapy approach for the treatment of severe cardiovascular disease. This investment builds on Jeito’s expertise in cardiology,...
by Manon FRACHON | 7 Jan Tue | English
Investment will support the ongoing Phase 2b/3 and planned pivotal Phase 3 clinical trial for AVD-104 in geographic atrophy secondary to age-related macular degeneration (AMD); Aviceda’s ongoing Phase 2b/3 trial evaluating AVD-104 is fully enrolled, with 12-month...
Recent Comments